Clinical Trials Logo

Tamoxifen clinical trials

View clinical trials related to Tamoxifen.

Filter by:
  • None
  • Page 1

NCT ID: NCT03528902 Completed - Hypertension Clinical Trials

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

T3PAH
Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated, and its impact on functional condition and selected biomarkers. Changes in tricuspid annular plane systolic excursion (TAPSE) and other parameters determined by transthoracic echocardiography will be evaluated as well as changes in additional metrics such as six minute walk test distance, quality of life assessments, and hormone levels.

NCT ID: NCT02166944 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Tamoxifen Treatment in Patients With Motor Neuron Disease

Start date: April 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to survey the effect of Tamoxifen in motor neuron disease (MND) patients, amyotrophic lateral sclerosis (ALS) with regular riluzole usage. TDP-43 is related to ALS. Increased the ubiquitinated or phosphorylated TDP-43 can cause animal model of ALS, and TDP43 can be degraded either by proteasome or autophagy pathway system. Autophagy pathway can be activated by mTOR inhibition, resulting in ameliorating TDP-43 accumulation and rescue in motor function in animal model. Tamoxifen had shown ability of enhance both proteasome and autophagy pathway, therefore the investigators assume that Tamoxifen probably can ameliorate TDP-43 accumulation and inclusion body formation in ALS.

NCT ID: NCT00973037 Recruiting - Breast Neoplasms Clinical Trials

CYP2D6 Genotype on the Clinical Effect of Tamoxifen

ASTRRA-CYP2D6
Start date: March 2009
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the impact of CYP2D6 Genotype on the clinical effects of tamoxifen using with samples from prospective randomized multicenter study(ASTRRA).

NCT ID: NCT00830973 Completed - Breast Neoplasms Clinical Trials

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

MHSLabCorp1
Start date: October 2007
Phase: N/A
Study type: Observational

This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast cancer.